# FLNA catalysts: FILANA THERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/flna/catalysts

> FILANA THERAPEUTICS, INC. (FLNA) has no upcoming catalysts in this calendar. The latest recorded is the FILANA THERAPEUTICS, INC. earnings report, November 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | FILANA THERAPEUTICS, INC. |
| Ticker | FLNA (Nasdaq) |
| SEC CIK | 1069530 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/flna |

## Cash runway

Cash $47.0M as of 2026-09-30; quarterly burn $6.1M; about 23.1 months of runway at that rate (XBRL company facts, accession 0001437749-26-035262).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 25, 2024 | [Simufilam topline data readout](https://sec-api.dev/pdufa/simufilam) | FLNA |  | completed, missed | "On November 25, 2024, we announced that the top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1069530/000143774925005919/sava20241231c_10k.htm)) |
| March 3, 2025 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Cassava Sciences Reports 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/exh_991.htm)) |
| March 25, 2025 | [Simufilam topline data readout](https://sec-api.dev/pdufa/simufilam) | FLNA | mild-to-moderate Alzheimer's disease | completed, missed | "On March 25, 2025, the Company announced that the topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1069530/000117184325001678/f8k_032525.htm)) |
| Q2 2025 | [Simufilam topline data readout](https://sec-api.dev/pdufa/simufilam) | FLNA |  | scheduled | "Following the release of the topline RETHINK-ALZ and REFOCUS-ALZ results, the Company announced the decision to phase out the Company's Alzheimer's disease development program, which we expect to be completed by the end of the second quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1069530/000143774925015478/sava20250331_10q.htm)) |
| May 8, 2025 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184325002954/exh_991.htm)) |
| August 14, 2025 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184325005406/exh_991.htm)) |
| November 12, 2025 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- - Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ended September 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184325007222/exh_991.htm)) |
| March 12, 2026 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/exh_991.htm)) |
| May 7, 2026 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Filana Therapeutics Reports Q1 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184326003119/exh_991.htm)) |
| July 29, 2026 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/exh_991.htm)) |
| November 5, 2026 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184326007150/exh_991.htm)) |

## Drugs

- [Simufilam](https://sec-api.dev/pdufa/simufilam): mild-to-moderate alzheimer's disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/flna/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FLNA catalysts: FILANA THERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/flna/catalysts

```bibtex
@misc{secapidev_companies_flna_catalysts_20261116,
  title        = {FLNA catalysts: FILANA THERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/flna/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_flna_catalysts_20261116","title":"FLNA catalysts: FILANA THERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/flna/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
